Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971133 | 0.82 | ALDH1A1 (0.30) | ADH1BADH1CADH1ACYP2D6 | |
| SCHEMBL24724878 | 0.79 | ADH1B (0.36) | ADH1BADH1CADH1A | |
| SCHEMBL3421028 | 0.74 | ADH1B (0.38) | ADH1BADH1CADH1AANPEPCYP2D6 | |
| SCHEMBL15861930 | 0.74 | ADH1B (0.38) | ADH1BADH1CADH1AANPEPCYP2D6 | |
| SCHEMBL18768100 | 0.73 | ADH1B (0.32) | ADH1BADH1CADH1A | |
| SCHEMBL9936326 | 0.72 | — | — | |
| SCHEMBL21727078 | 0.71 | ADH1B (0.34) | ADH1BADH1CADH1A | |
| SCHEMBL21015978 | 0.70 | ADH1B (0.35) | ADH1BADH1CADH1AANPEP | |
| SCHEMBL23046330 | 0.70 | ADH1B (0.35) | ADH1BADH1CADH1AANPEP | |
| SCHEMBL3422570 | 0.70 | ANPEP (0.35) | ADH1BADH1CADH1AANPEPCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023147597-A2 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| US-10550071-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180170857-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170857-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | ADH1B 938/4885ADH1C 1357/4885ADH1A 998/4885 |
| US-10550071-B2 | PPAR agonists | PPARG, PPARD, PPARA | ADH1B 938/4885ADH1C 1357/4885ADH1A 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.